Ezetimibe

Papers on ezetimibe

294 papers104 new in 30 days

Thursday, November 19

Tuesday, November 17

Friday, November 13

Wednesday, November 11

Tuesday, November 10

Monday, November 9

AHA Scientific Sessions 2026 Abstract

Evolocumab linked to fewer deaths in high-risk adults

Over three years, deaths occurred in 1.4% of evolocumab users versus 2.7% of alirocumab users across 2,610 matched pairs.Over three years, deaths occurred in 1.4% of evolocumab users versus 2.7% of alirocumab users across 2,610 matched pairs.

Artery cross-sections contain plaque and contrasting sparse and dense cholesterol particles, surrounded by small upright, faceless people.
Cohort studyEvolocumab
AHA Scientific Sessions 2026 Abstract

Very low “bad” cholesterol not linked to added cognitive risk

Cognitive impairment risk was similar—a hazard ratio of 1.00—at “bad” cholesterol below 30 mg/dL versus 30–55 mg/dL in adults with artery disease.Cognitive impairment risk was similar—a hazard ratio of 1.00—at “bad” cholesterol below 30 mg/dL versus 30–55 mg/dL in adults with artery disease.

Brains with similarly intact folds sit beside blood cells and sparse versus plentiful cholesterol particles.
Cohort studyPopulations

Saturday, November 7

Circulation

Two cholesterol drugs showed no clear cardiovascular advantage

Over three years, cardiovascular events occurred in 8.5% of patients starting statin–ezetimibe therapy versus 7.9% starting a statin alone.Over three years, cardiovascular events occurred in 8.5% of patients starting statin–ezetimibe therapy versus 7.9% starting a statin alone.

Artery sections with similar fatty buildup sit side by side, with sparse cholesterol particles in the larger section and denser particles in the smaller.
Randomized trial · 3,048 peopleAtherosclerotic cardiovascular disease